Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice

Maunder, H. E.; Taylor, Geraldine; Leppard, Keith N.; Easton, Andrew J.

doi:10.1016/j.vaccine.2015.10.105

Cited by 7 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst hRSV vaccine approaches can be studied in the mouse model of PVM, and vaccine candidates can be negatively selected, their ability to predict efficacy in higher species is not known. IN vaccination of mice with rAdV expressing either the M or N protein of PVM protected mice against a lethal challenge dose of PVM, although mice developed a transient weight loss [160].…”

Section: Non-human Pneumovirus Animal Modelsmentioning

confidence: 99%

Animal models of respiratory syncytial virus infection

Taylor

2017

Vaccine

Self Cite

160

150

View full text Add to dashboard Cite

show abstract

Section: Non-human Pneumovirus Animal Modelsmentioning

confidence: 99%

Animal models of respiratory syncytial virus infection

Taylor

2017

Vaccine

Self Cite

160

150

View full text Add to dashboard Cite

show abstract

“…Human respiratory syncytial virus vaccine development studies have been made on this model (Maunder et al., 2015; Martinez et al., 2016) including a model of FI-PVM enhanced respiratory disease, mediated by a Th2-biased response and eosinophil infiltration in lung (Percopo et al., 2009). Most recently, a replication deficient recombinant human adenovirus serotype 5 expressing the M or N protein of PVM pathogenic strain J3666, provided protection in mice, mediated mainly by CD8 + T cells (Maunder et al., 2015). However, there is still a limited number of studies in this field.…”

Section: Natural Host Pneumovirus Infectionsmentioning

confidence: 99%

Current Animal Models for Understanding the Pathology Caused by the Respiratory Syncytial Virus

et al. 2019

View full text Add to dashboard Cite

The human respiratory syncytial virus (hRSV) is the main etiologic agent of severe lower respiratory tract infections that affect young children throughout the world, associated with significant morbidity and mortality, becoming a serious public health problem globally. Up to date, no licensed vaccines are available to prevent severe hRSV-induced disease, and the generation of safe-effective vaccines has been a challenging task, requiring constant biomedical research aimed to overcome this ailment. Among the difficulties presented by the study of this pathogen, it arises the fact that there is no single animal model that resembles all aspects of the human pathology, which is due to the specificity that this pathogen has for the human host. Thus, for the study of hRSV, different animal models might be employed, depending on the goal of the study. Of all the existing models, the murine model has been the most frequent model of choice for biomedical studies worldwide and has been of great importance at contributing to the development and understanding of vaccines and therapies against hRSV. The most notable use of the murine model is that it is very useful as a first approach in the development of vaccines or therapies such as monoclonal antibodies, suggesting in this way the direction that research could have in other preclinical models that have higher maintenance costs and more complex requirements in its management. However, several additional different models for studying hRSV, such as other rodents, mustelids, ruminants, and non-human primates, have been explored, offering advantages over the murine model. In this review, we discuss the various applications of animal models to the study of hRSV-induced disease and the advantages and disadvantages of each model, highlighting the potential of each model to elucidate different features of the pathology caused by the hRSV infection.

show abstract

“…administration causes a PVM-specific CD8 response rather than increased serum IgG, which may result in the effective protection of mice after PVM challenge. 120 …”

Section: Preclinical Evaluation Of Intranasal Vaccinationmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effective in humans there are some issues that should be considered, such as the adjuvant, the route of vaccination, and the antigen-carrier system. While almost all licensed vaccines are injected such that inoculation is by far the most commonly used method, injection has several potential disadvantages, including pain, cross contamination, needlestick injury, under- or overdosing, and increased cost. It is also problematic for patients from rural areas of developing countries, who must travel to a hospital for vaccine administration. Noninvasive immunizations, including oral, intranasal, and transcutaneous administration of vaccines, can reduce or eliminate pain, reduce the cost of vaccinations, and increase their safety. Several preclinical and clinical studies as well as experience with licensed vaccines have demonstrated that noninvasive vaccine immunization activates cellular and humoral immunity, which protect against pathogen infections. Here we review the development of noninvasive immunization with vaccines based on live attenuated virus, recombinant adenovirus, inactivated virus, viral subunits, virus-like particles, DNA, RNA, and antigen expression in rice in preclinical and clinical studies. We predict that noninvasive vaccine administration will be more widely applied in the clinic in the near future.

show abstract

Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice

Cited by 7 publications

References 49 publications

Animal models of respiratory syncytial virus infection

Animal models of respiratory syncytial virus infection

Current Animal Models for Understanding the Pathology Caused by the Respiratory Syncytial Virus

Noninvasive vaccination against infectious diseases

Contact Info

Product

Resources

About